Trial Profile
A Pilot Study of Safety and Feasibility of Stem Cell Therapy for Aids Lymphoma Using Stem Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs HIV T-cell therapy (Primary) ; Carmustine; Cyclophosphamide; Etoposide; Filgrastim
- Indications Lymphoma; Non-Hodgkin's lymphoma; Plasmablastic lymphoma; Primary-Effusion-Lymphoma
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- 13 Nov 2019 Status changed from active, no longer recruiting to completed.
- 16 Aug 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
- 16 Aug 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.